Koji Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Koji Suzuki has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Daisuke Hagiwara
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
13 shared publications - Eri Sugiyama
National Cancer Center Japan
13 shared publications - Hidefumi Inaba
Wakayama Medical University 6 Department of Physiology Wakayama, Japan
13 shared publications - Hidetaka Suga
Department of Endocrinology and Diabetes, Graduate School of Medicine, Nagoya University, Nagoya, Japan
13 shared publications - Hiroki Izumi
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
13 shared publications - Hiroshi Arima
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine
13 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of HLA allele/haplotype frequency for the discovery cohort P+T and P groups treated with PD-1-Ab monotherapy
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of HLA allele/haplotype frequency for the discovery cohort P+T and P groups treated with PD-1-Ab monotherapy
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of overall survival by HLA subtype in patients with pituitary irAE
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of overall survival by HLA subtype in patients with pituitary irAE
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Some patients undergoing immune checkpoint blockade treatment develop immune-related adverse events (irAE) affecting multiple organs, but whether pituitary and thyroid dysfunction is prone to co-occur is unclear. A total of 1,014 patients treated at Nagoya University Hospital were prospectively assessed for pituitary and thyroid function, and human leukocyte antigens (HLA) were analyzed in patients with pituitary and/or thyroid irAEs. Pituitary irAE and thyroid irAE developed in 68 and 128 patients, respectively. The incidence of thyroid irAE was significantly higher in patients who developed pituitary irAE compared with those who did not [21/68 (30.9%) vs. 107/946 (11.3%), P < 0.001], and the difference remained significant with tumor type and therapeutic agents used as stratified factors (Cochran–Mantel–Haenszel test, P = 0.001). The frequencies of HLA-DRB1*15:01 (12.5% vs. 7.6%, P = 0.049) and DRB1*15:02 (16.9% vs. 10.6%, P = 0.025) were significantly higher in patients with pituitary irAE compared with those in a database containing Japanese subjects. The frequency of the DRB1*15:01-associated haplotype (DRB1*15:01-DQB1*06:02-DPB1*02:01) was significantly higher in patients who developed both pituitary and thyroid irAEs compared with the control (14.3% vs. 3.1%, P = 0.002), and the DRB1*15:02-associated haplotype (DRB1*15:02-DQB1*06:01-DPB1*09:01) frequency was significantly higher in patients who developed pituitary irAE but not thyroid irAE compared with the control (18.1% vs. 8.9%, P = 0.006); both findings were confirmed in the validation cohort comprising 92 patients with pituitary irAE from seven hospitals. In conclusion, pituitary and thyroid irAEs are prone to co-occur, and HLA-DR15–associated haplotypes are related to this co-occurrence.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Some patients undergoing immune checkpoint blockade treatment develop immune-related adverse events (irAE) affecting multiple organs, but whether pituitary and thyroid dysfunction is prone to co-occur is unclear. A total of 1,014 patients treated at Nagoya University Hospital were prospectively assessed for pituitary and thyroid function, and human leukocyte antigens (HLA) were analyzed in patients with pituitary and/or thyroid irAEs. Pituitary irAE and thyroid irAE developed in 68 and 128 patients, respectively. The incidence of thyroid irAE was significantly higher in patients who developed pituitary irAE compared with those who did not [21/68 (30.9%) vs. 107/946 (11.3%), P < 0.001], and the difference remained significant with tumor type and therapeutic agents used as stratified factors (Cochran–Mantel–Haenszel test, P = 0.001). The frequencies of HLA-DRB1*15:01 (12.5% vs. 7.6%, P = 0.049) and DRB1*15:02 (16.9% vs. 10.6%, P = 0.025) were significantly higher in patients with pituitary irAE compared with those in a database containing Japanese subjects. The frequency of the DRB1*15:01-associated haplotype (DRB1*15:01-DQB1*06:02-DPB1*02:01) was significantly higher in patients who developed both pituitary and thyroid irAEs compared with the control (14.3% vs. 3.1%, P = 0.002), and the DRB1*15:02-associated haplotype (DRB1*15:02-DQB1*06:01-DPB1*09:01) frequency was significantly higher in patients who developed pituitary irAE but not thyroid irAE compared with the control (18.1% vs. 8.9%, P = 0.006); both findings were confirmed in the validation cohort comprising 92 patients with pituitary irAE from seven hospitals. In conclusion, pituitary and thyroid irAEs are prone to co-occur, and HLA-DR15–associated haplotypes are related to this co-occurrence.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Distribution of pituitary and thyroid irAE grades in the discovery cohort
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Distribution of pituitary and thyroid irAE grades in the discovery cohort
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of HLA allele/haplotype frequency between patients in the discovery cohort who developed thyroid irAE and the Japanese controls
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of HLA allele/haplotype frequency between patients in the discovery cohort who developed thyroid irAE and the Japanese controls
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of HLA allele/haplotype frequency between patients in the discovery cohort who developed pituitary irAE and the Japanese controls
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of HLA allele/haplotype frequency between patients in the discovery cohort who developed pituitary irAE and the Japanese controls
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of HLA allele/haplotype frequency for the discovery cohort P+T and P groups vs. control group treated with immune checkpoint inhibitors
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of HLA allele/haplotype frequency for the discovery cohort P+T and P groups vs. control group treated with immune checkpoint inhibitors
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of HLA allele/haplotype frequency for the discovery cohort P+T and P groups treated with PD-1-/CTLA-4-Abs
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Comparison of HLA allele/haplotype frequency for the discovery cohort P+T and P groups treated with PD-1-/CTLA-4-Abs
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Author associations with Nagoya University-affiliated hospitals
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15–Related Haplotypes
Author associations with Nagoya University-affiliated hospitals